Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.46 |
| ▸ | ACKR3 | P25106 | 2/20 | 0.43 |
| ▸ | CNR1 | P21554 | 8/20 | 0.43 |
| ▸ | CNR2 | P34972 | 8/20 | 0.43 |
| ▸ | NPC1 | O15118 | 2/20 | 0.41 |
| ▸ | MAPT | P10636 | 1/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.40 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.40 |
| ▸ | BRD4 | O60885 | 1/20 | 0.40 |
| ▸ | RAB9A | P51151 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1642131 | 0.87 | CNR1 (0.51) | CNR1CNR2NPC1MAPTBRD4 | |
| SCHEMBL1642163 | 0.86 | CNR1 (0.52) | TDP1CNR1CNR2 | |
| SCHEMBL1642256 | 0.83 | MEN1 (0.49) | CNR1CNR2NPC1MAPTRAB9A | |
| SCHEMBL1642112 | 0.80 | EGLN3 (0.45) | CNR1CNR2BRD4 | |
| SCHEMBL1641956 | 0.79 | KDM4E (0.47) | MAPTSMN1; SMN2BRD4 | |
| SCHEMBL1642081 | 0.77 | ALDH1A1 (0.53) | CNR1CNR2NPC1MAPTMAPK1 | |
| SCHEMBL1641067 | 0.77 | CNR1 (0.65) | CNR1CNR2NPC1MAPTSMN1; SMN2 | |
| SCHEMBL1640740 | 0.75 | CNR1 (0.63) | CNR1CNR2NPC1MAPTSMN1; SMN2 | |
| SCHEMBL1642162 | 0.75 | LMNA (0.43) | CNR1CNR2NPC1RAB9A | |
| SCHEMBL1642259 | 0.75 | CNR1 (0.60) | CNR1CNR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110098324-A1 | PROLYL HYDROXYLASE INHIBITORS | GLAXOSMITHKLINE LLC | 2011-04-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110098324-A1 | PROLYL HYDROXYLASE INHIBITORS | HIF1AN, EGLN2, EGLN3 | TDP1 2395/4885ACKR3 3406/4885CNR1 2636/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.